Immutep's Efti combined with Keytruda achieved a 35.5% response rate in head and neck cancer patients without PD-L1 expression.
Immutep's Efti combined with Keytruda achieved a 35.5% response rate in head and neck squamous cell carcinoma patients with negative PD-L1 expression, according to RECIST 1.1 criteria. The combination had a 9.7% complete response rate and 25.8% partial response rate, with a disease control rate of 58.1%. Immutep's treatment approach does not contain chemotherapy and is among the highest recorded for such treatments.
July 11, 2024
4 Articles